智翔金泰(688443) - 2024 Q4 - 年度业绩

Financial Performance - Total revenue for 2024 reached RMB 30,094,960.63, a significant increase of 2384.10% compared to RMB 1,211,502.42 in the previous year[3] - The company reported a net loss attributable to shareholders of RMB 800,449,029.93, a slight improvement of 0.11% from the previous year's loss of RMB 801,319,298.24[3] - Basic earnings per share decreased to -RMB 2.18, down 12.80% from -RMB 2.50 in the prior year[3] - The company's total assets decreased by 12.49% to RMB 3,145,716,912.53 from RMB 3,594,596,738.24 at the beginning of the period[3] - Shareholders' equity attributable to the parent company fell by 23.75% to RMB 2,122,867,387.53 from RMB 2,784,232,358.39[3] - The weighted average return on net assets improved by 25.07 basis points to -32.80% from -57.87%[3] Research and Development - The company maintained a high level of R&D investment as multiple products entered clinical research and key clinical trial phases[5] - The significant increase in revenue was primarily due to the approval and sales of the product "赛立奇单抗注射液" (金立希®), which was not present in the previous year's revenue[5] Audit and Caution - The company emphasizes that the financial data is preliminary and subject to final audit in the annual report[6] - Investors are advised to be cautious as the reported figures are not yet audited and may be subject to change[6]